WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europ...
WuXi XDC opened lower and fell sharply in the morning session, hitting an intraday low of HK$49.36 (-6.9%), before recovering in the afternoon to close at HK$51.95, down 1.98%. The stock remains 39.24% below its 52-week high of HK$85.5 and trades below both its 20-day (HK$57.27) and 60-day (HK$54.46) moving averages. Recent target price cuts from Nomura (to HK$82.6) and Morgan Stanley (to HK$80) on adverse FX impact, along with repeated share issuances (multiple HKEX filings in recent weeks) raising dilution concerns, pressured sentiment. However, Q4 earnings showed strong fundamentals: revenue surged 42.02% YoY to HK$1.8bn, net profit rose 32.11% YoY, and ROE remained at 13.7%, while BOCOM International reaffirmed its Buy rating.
WuXi XDC surged in the morning session, trading at HK$56.05 as of 10:01 BJ, up 5.16% from the previous close of HK$53.30, driven by robust Q4 2025 earnings: operating revenue of HK$1.80 billion (+42.02% YoY), net profit of HK$408.56 million (+32.11% YoY), and operating income jumping 69.15% YoY to HK$474.71 million. The stock has rebounded 30.96% from its 52-week low of HK$42.80 but remains 34.44% below the 52-week high of HK$85.50, and the current price of HK$56.05 is below the 20-day MA (HK$57.353), indicating near-term momentum lags the medium-term trend. However, a P/E of 43.3x and P/B of 5.98x suggest elevated valuation may cap further upside.
WuXi XDC opened lower and extended losses, plunging 5.3% in the morning session to HKD 56.15, underperforming the broader market. The decline was mainly driven by benchmark pullback pressure and profit-taking after a recent rally, rather than a deterioration in fundamentals. The stock had surged over 8% intraday in the prior session, triggering today's sharp correction. Despite BOCOM International reiterating its Buy rating, and Daiwa naming it a top pick in the CXO sector with a target of HKD 82.6, the stock remains 34.3% below its 52-week high of HKD 85.5 and is down 8.5% year-to-date, trading below its 20-day moving average of HKD 57.0, signaling short-term technical weakness. However, the company's latest quarterly revenue grew 42% YoY and net profit rose 32%, contrasting with the current price weakness.
WuXi XDC fell sharply in the afternoon session, closing at HKD 59.6, down 4.87% from the previous close, with an intraday high of HKD 62.7 and low of HKD 59.4, showing a spike-and-retreat pattern. The sell-off was mainly driven by negative sentiment from BOCOM International maintaining a Buy but keeping the target price unchanged at HKD 80, and Morgan Stanley cutting its 2026-30 earnings forecasts and lowering the target price to HKD 80. On the fundamentals, Q4 2025 revenue grew 42.02% YoY to HKD 1.80 billion, net profit rose 32.11% YoY, and EPS increased 27.86% YoY, indicating strong operational momentum. The stock is now trading below both its 20-day (HKD 56.534) and 60-day (HKD 55.235) moving averages, with YTD decline of 2.85% and a 30.29% drawdown from the 52-week high of HKD 85.5, though it still holds a 39.42% gain from the 52-week low of HKD 42.75.
WuXi XDC (2268.HK) rallied 5.0% in the morning session, opening at the intraday low of HK$58.80 and climbing steadily to HK$61.55, driven by a wave of bullish analyst reports and sector-wide CXO optimism. UBS maintained a Buy rating and named it the top CXO pick; Daiwa initiated with a Buy and HK$82.6 target; Morgan Stanley trimmed its target to HK$80 but the overall tone remained constructive. Q4 2025 revenue surged 42.02% YoY to HK$1.80bn, with net profit up 32.11% YoY to HK$409mn and a net margin of 22.7%. At HK$61.45, the stock trades above its 20-day (HK$55.81) and 60-day (HK$55.23) moving averages but remains 28.1% below the 52-week high of HK$85.5, with YTD change flat at +0.16%. However, multiple share issuances recently disclosed may weigh on near-term sentiment.
Nomura Cuts WUXI XDC TP to HKD82.6 on Adverse FX Impact on Earnings
WuXi Advanced Therapies rises over 8% to HK$57.60
WuXi XDC Falls 10% as CRO Sector Retreats
WuXi XDC falls 8% on share dilution, CMB downgrade
WuXi XDC files HKEX next-day disclosure return, share capital rises by 1,121,205 shares
BOCOM International Holdings Company Reaffirms Their Buy Rating on WuXi XDC Cayman, Inc. (2268)